UBS Group
VBIO

UBS Group’s Valion Bio VBIO Stock Holding History

UBS Group’s Portfolio VBIO Stock Details VBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.1K Sell
2,366
-17,293
-88% -$17.7K ﹤0.01% 9359
2025
Q4 		$28.5K Buy
19,659
+18,858
+2,354% +$43K ﹤0.01% 7557
2025
Q3 		$2.31K Sell
801
-4,852
-86% -$16.7K ﹤0.01% 9187
2025
Q2 		$23.5K Buy
+5,653
New +$24.3K ﹤0.01% 8331
2025
Q1 		– Sell
-3,224
Closed -$19K – 10727
2024
Q4 		$19K Sell
3,224
-2,323
-42% -$10.8K ﹤0.01% 7913
2024
Q3 		$23.6K Sell
5,547
-885
-14% -$5.34K ﹤0.01% 7274
2024
Q2 		$42.6K Buy
+6,432
New +$81K ﹤0.01% 6823
2024
Q1 		– Sell
-13
Closed -$391 – 10009
2023
Q4 		$391 Buy
13
+6
+86% +$173 ﹤0.01% 8689
2023
Q3 		$208 Sell
7
-10
-59% -$739 ﹤0.01% 8701
2023
Q2 		$3.14K Sell
17
-61
-78% -$13.1K ﹤0.01% 7660
2023
Q1 		$20.1K Buy
78
+76
+3,800% +$53.3K ﹤0.01% 7075
2022
Q4 		$2.3K Hold
2
– – ﹤0.01% 9704
2022
Q3 		$6K Buy
2
+1
+100% +$3.38K ﹤0.01% 9068
2022
Q2 		$4K Buy
+1
New +$2.93K ﹤0.01% 9131
2022
Q1 		– Sell
-3
Closed -$18K – 10899
2021
Q4 		$18K Buy
+3
New +$22K ﹤0.01% 7991

Other funds holding VBIO

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $18.5B AUM 23.32% 1-Year Est. Return
MG
Marex Group London $15.8B AUM 31.44% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $541M AUM 1,009.51% 1-Year Est. Return

UBS Group's VBIO Position: Q1 2026 in Review

UBS Group reduced its Valion Bio (VBIO) stake by 88% in Q1 2026, selling an estimated $17.7K and leaving 2,366 shares worth $2.1K. The position accounts for ﹤0.01% of the portfolio, ranked #9359.

UBS Group first reported a position in VBIO in Q4 2021 and has held it in 15 quarters since. The position peaked at $42.6K in Q2 2024. 9 funds tracked by Wall St. Rank hold VBIO as of Q1 2026.

  • UBS Group held 2,366 shares of Valion Bio worth $2.1K as of Q1 2026.
  • UBS Group sold 17,293 Valion Bio shares in Q1 2026, an estimated $17.7K.
  • Valion Bio made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #9359 holding.
  • UBS Group first reported a position in Valion Bio in Q4 2021 and has held it in 15 quarters since.
  • UBS Group's Valion Bio position peaked at $42.6K in Q2 2024.
  • 9 funds tracked by Wall St. Rank held Valion Bio as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.